Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Clinical trial NCT07504588 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07504588
Sponsor: National Cancer Institute (NCI)
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma

Start date: 2026-09-10
Primary completion: 2029-04-12
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.